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Abstract
Adenoviral vectors have shown a great potential for vaccine development due to their inherent ability to induce potent and
protective CD8 T-cell responses. However, a critical issue regarding the use of these vectors is the existence of inhibitory
immunity against the most commonly used Ad5 vector in a large part of the human population. We have recently
developed an improved adenoviral vaccine vector system in which the vector expresses the transgene tethered to the MHC
class II associated invariant chain (Ii). To further evaluate the potential of this system, the concept of pre-existing inhibitory
immunity to adenoviral vectors was revisited to investigate whether the inhibition previously seen with the Ad5 vector also
applied to the optimized vector system. We found this to be the case, and antibodies dominated as the mechanism
underlying inhibitory vector immunity. However, presence of CD8 T cells directed against epitopes in the adenoviral vector
seemed to correlate with repression of the induced response in re-vaccinated B-cell deficient mice. More importantly,
despite a repressed primary effector CD8 T-cell response in Ad5-immune animals subjected to vaccination, memory T cells
were generated that provided the foundation for an efficient recall response and protection upon subsequent viral
challenge. Furthermore, the transgene specific response could be efficiently boosted by homologous re-immunization.
Taken together, these studies indicate that adenoviral vectors can be used to induce efficient CD8 T-cell memory even in
individuals with pre-existing vector immunity.
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Introduction
Development of effective vaccines against diseases such as HIV,
hepatitis C and cancer will require vaccine formulations capable of
inducing effective and long lasting cellular immunity. Most current
effective vaccines are protective primarily due to the induction of
antibodies against the targeted pathogen. However, several
diseases cannot be effectively prevented or treated by an antibody
response alone, and at present time, vaccines which are effective
against these types of diseases do not exist. There are only few
vaccine vectors capable of inducing efficient and long lasting
cellular immunity, and one of these is the replication-incompetent
adenovirus serotype 5 vector (Ad5). However, a major issue
concerning the use of this vector is that there have been several
reports from experimental studies indicating that prior contact
with this virus may inhibit the generation of an immune response
induced through vaccination [1–5]. Since a large fraction of the
human population has encountered Ad5 naturally, they will also
have pre-existing Ad5 immunity [6,7]. Moreover, even if the use of
vaccine vectors based on other adenoviral serotypes should
become common practice in order to overcome this problem,
the issue of pre-existing immunity is also relevant with regard to
these serotypes. It is therefore extremely import to clearly define
the extent to which pre-existing immunity may represent a barrier
to adenoviral vaccination, the underlying mechanisms, and how
inhibitory immunity may be circumvented.
Vaccination with a high dose of empty Ad5 vector has been
shown to induce high titers of antibodies directed against the Ad5
capsid proteins [1–4], primarily the hexon protein [8], leading to a
substantially inhibited primary immune response upon vaccination
with antigens encoded by the Ad5 vector. However, it is not yet
quite clear whether this inhibitory effect is also marked with regard
to the generation of memory T cells and recall responses in Ad5
vaccinated individuals. Furthermore, various observations indicate
that neutralizing antibodies are not the sole contributors to the
observed inhibition [2,3,9], making the issue of inhibitory
immunity more complex. Notably, previous studies have used
the intramuscular route of vaccination, which might impact the
results obtained from these studies, since muscle tissue has a high
blood supply. On the one hand this could mean a greater risk of
virus dissemination, but also that antibodies and immune cells
would have more easy access to the site of vaccination. In this
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suggest that keeping the vector inoculums very localized as in the
case of subcutaneous vaccination may in fact be a much better way
to administer Ad vaccination [10]. It is therefore pertinent to
establish whether the inhibitory effect of pre-existing immunity is
just as pronounced when adenoviral vectors are given subcutane-
ously.
In the current study, we have used an optimized adenoviral
vaccine vector system in which the vector expresses the
glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV)
tethered to the MHC class II associated invariant chain (Ii). This
substantially enhances the CD8 T-cell response induced by the
vector [11] and could therefore, in theory, also improve the
vector’s ability to overcome inhibitory immunity caused by prior
encounter with the vector. It has recently been shown, that in the
presence of pre-existing immunity, the branch of the cellular
immune response that is most affected, is the CD8 T-cell response
[12]. It is therefore of great importance to establish a vector system
that is capable of overcoming this phenomenon, in order to create
successful vaccine formulations capable of combating diseases such
as HIV, hepatitis C and cancer, in which a potent and sustained
CD8 T-cell response is crucial for elimination of virus infected or
malignant cells.
For this reason, the concept of pre-existing inhibitory immunity
to adenoviral vectors was revisited. While confirming earlier
observations indicating that pre-existing antibodies represent the
major suppressive factor [3], we also obtained results suggesting
that adenovirus-specific T cells could play a significant role. More
importantly, despite a repressed primary effector CD8 T-cell
response in Ad-immune animals subjected to vaccination, memory
T cells are still generated, which can efficiently provide the
foundation for an improved immune response upon subsequent
viral challenge. Additionally, in contrast to the existing literature
[13], we observed efficient boosting of the transgene specific CD8
T-cell response following homologous re-immunization. Thus,
there is every reason to assume that genetically modified
adenoviruses may serve as efficient vaccine vectors inducing
CD8 T-cell memory and protective immunity even in the presence
of pre-existing antibodies to certain serotypes in a large percentage
of the human population.
Materials and Methods
Ethics statement
Experiments were conducted in accordance with national
Danish guidelines (Amendment # 1306 of November 23, 2007)
regarding animal experiments as approved by the Danish Animal
Experiments Inspectorate, Ministry of Justice, permission numbers
2004/561–867 and 2009/561–1679.
Mice
Female C57BL/6 mice were obtained from Taconic Farms.
B6.129S2-Igh-6tm1Cgn/J (B-cell deficient) mice were obtained
from The Jackson Laboratory. All mice used in this study were
about 8 weeks old when included in an experiment and housed in
a specific pathogen-free facility.
Adenoviral vectors and vaccination
Replication deficient E1-deleted Ad5 vectors with a non-
functional E3 gene expressing either a truncated version of
ovalbumin (Ova) or the GP of LCMV linked to Ii (designated Ad5-
IiOva and Ad5-IiGP, respectively) were produced as described
previously [14]. For production of the Ad35-IiGP vector, the IiGP
insert was excised from the pacCMV plasmid via restriction
enzymes and cloned into the pHMCMV5 plasmid (kindly
provided by Hiroyuki Mizuguchi, Ph.D, Osaka University, Osaka,
Japan), the shuttle vector for the Ad35 vector cloning system, that
was originally developed by Mizuguchi and Kay [15,16]. From the
shuttle vector, the insert was cloned directly into the E1 deleted
Ad35 backbone (kindly provided by Hiroyuki Mizuguchi, Ph.D)
via homing endonucleases PI-Sce I and I-Ceu I. The Ad35-IiGP
DNA was transfected into Hek-E1b cells (kindly provided by
Hiroyuki Mizuguchi, Ph.D) to support production of virus
particles. Adenoviral particles were purified using standard
methods and aliquoted and frozen at 280uC in 10% glycerol.
The IiGP insert sequence was verified by sequencing and
restriction enzyme digestion. Infectivity of the adenovirus stocks
was determined with the Adeno-X
TM Rapid Titer Kit (Clontech
Laboratories Inc., California, USA). The ratio of physical particles
to infectious units for the adenoviral vaccines used in this study
varied between 50 and 100.
In the majority of experiments mice to be vaccinated were
anesthetized and injected with 2610
7 infectious units of Ad5
vector in 30 ml PBS s.c. in the hind foot pad; mice vaccinated using
Ad35 vector received 5610
8 infectious unit of virus in the same
manner. Mice to be vaccinated a second time received the
injection in the contra lateral foot pad.
Viruses
In addition to adenovirus, vaccinia virus and LCMV were
utilized in this study. Vaccinia virus expressing the GP of LCMV
(VV-GP) was kindly provided by A. Oxenius (ETH, Zu ¨rich,
Switzerland). The virus was grown and titered using CV-1 cells.
For infection of mice, a dose of 10
6 pfu was given i.p. LCMV
clone 13 was originally provided by M.B.A. Oldstone (The Scripps
Research Institute, La Jolla, CA) and further propagated in-house
using BHK cells. For infection of mice, a dose of 10
6 pfu was given
i.v.
LCMV organ titers
Organs were homogenized as 10% organ suspensions, and viral
titers were determined using an immune focus assay as previously
described [17].
Dendritic cell preparation
Femurs from mice were removed aseptically and purified from
the surrounding tissue. The bone marrow was flushed out using a
syringe filled with HBSS and single-cell suspensions were obtained
by pressing the spleen through a fine steel mesh (70 mm), followed
by centrifugation and resuspension in RPMI 1640 cell culture
medium containing 10% FCS supplemented with NaHCO3,2 -
ME, L-glutamine, and penicillin-streptomycin. 6610
6 cells were
seeded in non-coated 175 cm
2 cell culture flasks containing 30 ml
cell medium supplemented with 20 ng/ml GM-CSF. Cell culture
flasks were incubated at 37uC and 5% CO2, and were
supplemented with fresh medium containing GM-CSF on days
3, 6 and 8 after cell purification [18]. On day 10, dendritic cells
were washed and resuspended in medium containing 100 MOI
(multiplicity of infection) of Ad5-IiGP. Cells and virus particles
were incubated for 6 hours at 37uC and 5% CO2, followed by 3
washes and resuspension in PBS. Cell number was adjusted to
50610
6/ml and 100 ml were injected s.c. in the right flank of
recipient mice.
Flow cytometry
After vaccination of mice with Ad5-IiOva/GP or DCs, the
frequencies of epitope specific CD8+ T cells were determined by
Pre-Existing Vector Immunity and CD8 T-Cell Memory
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peptides (0.1 mg/ml GP33, GP276 or FALSNAEDL (CD8 T cell
epitope in DBP of Ad5)) at 37uC and 5% CO2. After incubation,
the cells were stained with Abs for cell surface markers (PerCP-
Cy5.5-CD8 and FITC-CD44) and Ab for intracellular cytokine
(APC-IFN-c). Samples were run on FACSCalibur or LSRII flow
cytometers (BD biosciences) and analyzed using Cellquest Pro (BD
biosciences) or FlowJo software (Tree Star). Phenotype character-
ization of IFN-c
+ CD8 T cells was performed using the following
markers: FITC-CD27, PE-Cy7-CD127 and PE-KLRG-1.
Statistical evaluation
Data are presented as individual points each representing one
animal. A nonparametric Mann–Whitney U test was used to
compare quantitative data; *p, 0.05 and **p, 0.01. GraphPad
Prism version 4 was used for statistical analysis.
Results
Prior encounter with adenovirus inhibits the induction of
a transgene-specific primary immune response using the
same vector
Based on the fact that tethering of the transgenic antigen to
invariant chain markedly improves the transgene-specific immune
response, we hypothesized that the same degree of virus
neutralization, which would completely prevent vaccination with
a classical vector construct would still allow efficient priming with
our optimized vector. As a first experiment to test this assumption
we did a dose-response experiment, in which groups of mice were
vaccinated with decreasing dose of Ad5- IiGP or Ad5-GP.
Fourteen days later the transgene-specific CD8 T-cell response
was measured. As can be seen in Fig. 1, a 100-fold reduction in
inoculum, from the 2610
7 infectious units normally used for
immunization to 2610
5 infectious units, still allowed the induction
of a substantial transgene-specific CD8 T-cell response when we
used Ad5-IiGP, whereas the same reduction in the dose of Ad5-
GP completely eliminated an immune response. Thus, assuming
as much as 99% neutralization of the incoming inoculum, the
optimized vector should still induce a sizable CD8 T-cell response
directed towards the inserted transgene.
To directly test this prediction, mice were initially vaccinated
with an irrelevant vector, Ad5-IiOva, followed by a second
vaccination with Ad5-IiGP 40 days later. The GP-specific CD8 T-
cell response was measured 11 days later and compared to the
response in matched, vector-naı ¨ve mice. As expected (Fig. 2), the
GP-specific CD8 T-cell response was clearly inhibited in mice
previously exposed to Ad5. The inhibition of the vector induced
immune response was more pronounced for the GP276 specific
response resulting in a ,9 fold reduction of CD8 T-cell numbers
versus a ,5 fold reduction in numbers of GP33 specific CD8 T
cells (Fig. 2A;representative dot plots can be seen in Fig. 2B); for a
more extensive analysis of the degree of inhibition, please see Fig.
S1. Nevertheless, despite these reductions a distinct transgene-
specific CD8 T-cell response was observed in the majority of
vector immune mice (Fig. 2 and Fig. S1.)
Inhibitory immunity primarily, but not exclusively reflects
the presence of virus-specific antibodies
Having confirmed that previous encounter with Ad5 reduces
the vaccine-induced response in most mice, we proceeded to
examine the underlying mechanism(s). Both neutralizing antibod-
ies and T cells have previously been implicated in the inhibition
observed when vaccinating with adenoviral vectors in previously
immunized mice [2,3], and we therefore wanted to see if both
mechanism were also relevant in our system. To address this issue,
two complementary experimental set-ups were applied, which
would separate the effect of antibodies from other specific
immunological factors.
In the first set-up, mice were vaccinated with Ad5-IiOva, and 40
days later, serum was transferred to naı ¨ve mice so that each
recipient received 1 ml serum in total (0.5 ml i.v. and 0.5 ml i.p.).
As shown previously by Thomsen et al. [19], transfusion of this
amount of serum should result in an antibody titer in the
circulation of the recipients, which is about one third of the
concentration in donor serum. One day after serum transfer,
recipients were vaccinated with Ad5-IiGP and the GP specific
CD8 T-cell response was measured on day 11 after vaccination. A
group of mice receiving serum from naı ¨ve animals was included as
a control. As can be seen in Fig. 3, the CD8 T-cell response was
significantly inhibited in mice that received serum from previously
immunized mice, while control serum had no inhibitory effect.
The inhibition caused by serum transfer was not as pronounced as
that seen in previously vaccinated mice, which may reflect of the
lower antibody concentration mentioned above or that T cells also
contribute to this phenomenon.
Complementary to the serum transfer approach, B cell deficient
mice were vaccinated with Ad5-IiOva (or Ad5-IiGP) followed by a
second vaccination with Ad5-IiGP or Ad5-IiNP on day 40. The
group receiving Ad5-IiOva followed by Ad5-IiNP, received a third
vaccination with Ad5-IiGP 40 days after the second immunization.
The GP specific CD8 T-cell response was measured on day 11
after the final vaccination (second or third). The experimental
design and timeline can be seen in Fig. 4. In the previous
experiments involving inhibitory pre-immunity, we had also tested
whether there would be a measurable T-cell response directed
against an epitope in the adenoviral backbone. In those
experiments we had observed very low, barely detectable
responses in wt mice (data not shown); however, we wanted to
see whether this response would be higher when humoral
immunity was absent. Therefore, the Ad5-specific CD8 T-cell
response was also measured on day 11 after the final vaccination.
In the absence of antibodies, Ad5 vaccination resulted in a
normal, unimpaired GP33 specific CD8 T-cell response in vector
immune mice (Fig. 4A), whereas the GP276 specific response
Figure 1. Dose-response correlations for Ad5-IiGP and Ad5-GP
vectors. Groups of mice were vaccinated with the indicated vector
doses and 14 days later the mice were sacrificed and the splenocytes
were stimulated in vitro for 5 hrs. using the indicated epitopes.
Antigen-specific CD8 T cells were enumerated using intracellular
cytokine staining for IFN-c.
doi:10.1371/journal.pone.0034884.g001
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difference to naı ¨ve mice was not statistically significant (Fig. 4B).
The latter finding could suggest that, at least in the absence of
antibodies, there was also a weak T-cell based component involved
in the inhibitory effect of prior vaccination with adenovirus.
Consistent with this possibility, we also saw a significantly increased
Ad5specificCD8T-cellresponseinpre-immunizedmicecompared
to mice receiving only one vaccination with adenovirus (Fig. 4C).
Mice receiving 3 vaccinations with Ad5 vectors expressing three
different exogenous antigens were included to see if the number of
Ad5 specific CD8 T cells would increase proportionally to the
number of vaccinations. At the time-point selected for analysis
(day 11 after last vaccination), we did not observe a significant
difference in the number of adenovirus-specific CD8 T cells
between the groups receiving two or three vaccinations (Fig. 4C),
but we did see a further inhibition of the GP specific CD8 T-cell
response in the latter group (Fig. 4A+B), consistent with the notion
that there might have been more Ad5 specific T cells present at the
time of Ad5-IiGP vaccination in this group of mice. This adds
further to the idea that Ad5 specific CD8 T cells might play a role
in the inhibition, at least in mice unable to produce antibodies.
Vaccination with adenovirus infected dendritic cells
overcomes inhibitory immunity in previously vaccinated
mice
The above results point to antibodies as the major mechanism
underlying the inhibition of vaccine-induced immune responses in
vector-immune mice. If that is the case, masking the adenoviral
vector inside dendritic cells (DCs) should circumvent the problem.
To test this prediction, mice were immunized with Ad5-IiOva
followed by a subcutaneous injection with Ad5-IiGP infected DCs
40 days later. The GP specific CD8 T-cell response was measured
on days 8 and 11 after DC injection. Consistent with a major role
for neutralizing antibodies, we saw no significant inhibition of the
DC induced GP response for either of the epitopes tested in
vector-immune mice compared to naı ¨ve controls (Fig. 5).
Figure 2. Prior encounter with adenovirus serotype 5 inhibits the induction of a primary transgene-specific CD8 T cell response
using the same vector. Mice were initially vaccinated with either Ad5-IiOva followed by a second vaccination with Ad5-IiGP 40 days later. The GP-
specific CD8+ T cell response was measured on days 11. (A) GP-specific CD8 T cell numbers in the spleen. B) Representative dot plots of gated CD8 T
cells following in vitro stimulation in the presence or absence of GP33.
doi:10.1371/journal.pone.0034884.g002
Figure 3. Transfer of serum from Ad5 immunized mice inhibits the induction of a transgene-specific CD8 T cell response by the
same vector. Mice were vaccinated with Ad5-IiOva and 40 days later, serum (immune serum) was transferred to naı ¨ve mice so that each recipient
received 1 ml serum. One day after serum transfer, recipient mice were vaccinated with Ad5-IiGP and the GP- specific CD8 T cell response was
measured on day 11 after vaccination.
doi:10.1371/journal.pone.0034884.g003
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less affected than the expansion of primary effectors in
Ad5-immune mice
For vaccination purposes, the induction of a strong memory
response is the ultimate goal, and it was therefore of primary
importance to investigate to which extent a reduction in the
memory CD8 T-cell response would follow the reduction in the
primary response. To study this, mice were initially vaccinated
with Ad5-IiOva followed by a second vaccination with Ad5-IiGP
40 days later. The GP specific CD8 T-cell response was measured
60 days after the final vaccination. As previously seen with the
primary effector response, numbers of memory CD8 T cells were
significantly reduced in vector-immune animals (Fig. 6); however,
it is interesting to note that the difference in numbers of memory
CD8 T cells between previously vaccinated and naı ¨ve mice was
only in the order of ,3 fold compared to a difference ranging from
5–9 fold when it comes to the primary effector response (cf. Fig. 2).
This indicates that even though the acute transgene-specific
response is substantially inhibited in vector-immune mice, it seems
that the memory response stabilizes at a level closer to what is
induced in vector-naı ¨ve animals.
Efficient recall responses despite reduced memory T-cell
numbers in Ad5-immune mice vaccinated with the Ad5
vector
Having established that CD8 T-cell memory is somewhat
impaired in mice with pre-existing vector immunity, it was
pertinent to determine what this would mean in terms of reduced
responsiveness to a viral challenge. For this reason, mice were
initially vaccinated with Ad5-IiOva, followed by a second
vaccination with Ad5-IiGP on day 40. Sixty days after the second
vaccination, the mice were challenged using vaccinia virus
expressing GP of LCMV (VV-GP), and the GP specific CD8+
T-cell response was measured 6 days later. The experiment also
included groups receiving only Ad5-IiOva+Ad5-IiGP, Ad5-
IiGP+VV-GP and Ad5-IiGP or VV-GP alone. The experimental
design and timeline can be seen in Fig. 7.
Similar to the situation in mice primed when vector naive, the
GP specific CD8 T-cell response of mice with impaired priming is
also significantly boosted by vaccinia infection. Indeed, the GP33
specific recall response induced in these mice is nearly comparable
to that observed in mice receiving only one vaccination with Ad5.
The GP276 specific CD8 T-cell response can also be boosted in
mice that have a repressed GP response before the challenge;
however, in this case the number of secondary CD8 T cells
generated is ,5 fold lower than what is seen in mice with an
uninhibited GP276 response before the challenge. Nevertheless,
the most important finding in this experiment is that even though
previously Ad5-immune mice generate fewer trangene specific
memory CD8 T cells upon Ad5 vaccination, memory T cells are
induced and will provide an accelerated response to a viral
challenge.
To directly evaluate the functional capacity of the secondary
effector CD8 T cells generated in mice with preexisting immunity
towards the adenovector, we challenged mice primed with Ad5-
IiGP in the presence or absence of vector immunity with a high
dose (10
6 pfu) of LCMV clone 13 i.v. and measured the viral load
Figure 4. Prior encounter with adenovirus does not inhibit the induction of a transgene- specific CD8 T cell response by the same
vector in B cell deficient mice. B cell deficient mice were vaccinated with Ad5-IiOva followed by a second vaccination with Ad5-IiGP or Ad5-IiNP
on day 40. The group receiving Ad5-IiOva followed by Ad5-IiNP received a third vaccination with Ad5-IiGP 40 days after the second immunization.
The GP- or Ad5-specific CD8 T cell response was measured on day 11 after the final vaccination (second or third). The experimental design and
timeline is outlined above.
doi:10.1371/journal.pone.0034884.g004
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immunized with Ad5-IiOva followed by a subcutaneous injection with 5610
6 Ad5-IiGP infected DCs 40 days later. The GP-specific CD8 T cell response
was measured on days 8 and 11 after DC injection.
doi:10.1371/journal.pone.0034884.g005
Figure 6. Vaccine induced generation of transgene-specific memory CD8 T cells is less affected than the expansion of primary
effectors in Ad5-immune mice. Mice were initially vaccinated with Ad5-IiOva followed by a second vaccination with Ad5-IiGP 40 days later. The
GP-specific CD8 T cell response was measured 60 days after the final vaccination.
doi:10.1371/journal.pone.0034884.g006
Pre-Existing Vector Immunity and CD8 T-Cell Memory
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34884Figure 7. Efficient recall responses despite reduced memory T cell numbers in Ad5-immune mice vaccinated with the Ad5 vector.
Mice were initially vaccinated with Ad5-IiOva, followed by a second vaccination with Ad5-IiGP on day 40. A) Sixty days after GP vaccination, the mice
were challenged using vaccinia virus expressing GP of LCMV (VV-GP), and the GP-specific CD8+ T cell response was measured 6 days later. The
experimental design and timeline is outlined above. B) Alternatively, mice vaccinated as described 60 days earlier were challenged with 10
6 pfu of
LCMVclone 13 i.v., and 5 days later spleen and lung virus titers were analyzed. The dotted line represents 250 pfu (limit of detection).
doi:10.1371/journal.pone.0034884.g007
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controls. As can be seen in Fig. 7, infectious virus either could not
be detected in vaccinated mice (spleen), irrespective of pre-existing
vector immunity, or was found in minimal amounts only in mice
with pre-existing immunity (lungs); this is in sharp contrast to
unvaccinated mice, which harbor LCMV in high titers in both
organ sites. Since we have previously demonstrated that cytotoxic
CD8 T cells represent the key protective effector mechanism
under these conditions [20], the latter results strongly support the
concept that efficient and protective CD8 T-cell memory can be
induced even in individuals with preexisting immunity to the
adenoviral vector.
Pre-existing immunity does not prevent secondary
expansion of vaccine-specific CD8 T cells
Having confirmed that the primary CD8 T-cell response is
substantially inhibited in vector immune mice, whereas memory
generation is not, we found it pertinent to investigate whether Ad5
induced secondary expansion would be inhibited. To address this
question, mice were vaccinated with Ad5- IiGP, followed by a
second vaccination with the homologous vector on day 40. The
GP specific CD8 T-cell response was measured on days 5, 8 and
11 after the second vaccination. Contrary to expectations, a
homologues vaccine booster induced a significant acute expansion
of GP specific CD8 T-cell in pre-immunized mice, and the
response showed the accelerated kinetics typical of a secondary
response (Fig. 8A). Thus, significant T-cell expansion was observed
on day 5 post vaccination; this is in contrast to primary responses
induced by vaccination with this virus, in which case no response
can be observed at this time point [21]. However, re-vaccination
did not result in more effector cells being generated during recall
than during primary vaccination. From this observation, it is
would appear that there is some inhibition in pre-immune mice,
but not enough to completely abolish a secondary Ad5 induced
expansion.
In order to better appreciate the extent of the suppression of
recall responses exerted in mice subjected to re-vaccination, two
additional experiments were performed. In the first experiment
(Fig. 8B), mice primed using a serologically unrelated Ad35 vector,
Ad35-IiGP, were re-vaccinated using Ad5-IiGP vector about 2
month later, and the GP-specific CD8 T-cell response was
measured 5, 8 and 11 days later. Despite the poorer T-cell
priming known to follow the use of Ad35 vectors (ref), it is evident
that an accelerated recall response against GP33 was observed
following Ad5-IiGP vaccination, peaking at a level about twice
that in unprimed mice - (regarding the response to GP276 it is our
experience (personal observation) that Ad35 vaccination hardly
causes any priming and the response kinetics is therefore not
relevant in this context). Similarly, if B-cell deficient mice primed
with Ad5-IiGP were boosted using the same vector (Fig. 8C), we
also found a secondary response, which peaked at a level about
twice that in unprimed mice. Thus. both these observation support
the interpretation that a transgene-specific CD8 T-cell recall
response can be induced in vector immune animals, but the
induced response is reduced compared to that observed in mice
lacking vector-specific antibodies.
Memory cell expansion in previously vaccinated mice
We also investigated memory cell expansion following a booster
vaccination with Ad5-IiGP. Mice were vaccinated with Ad5-IiGP
followed by a second vaccination with the same vector 40 days
later, and the GP specific CD8 T-cell response was measured on
day 60 after the final vaccination. Controls consisted of mice
vaccinated once with the same vaccine either at the time of first
immunization, or simultaneously with the booster dose. As can be
seen in Fig. 9, numbers of GP276 specific memory CD8 T cells
were significantly higher after two vaccinations compared to a
single vaccination, indicating that it may be possible to expand the
memory pool even in pre-immune mice. The induced GP33
specific secondary memory CD8 T-cell response showed the same
tendency without being statistically significant (Fig. 9). This result
is in line with observations regarding the primary CD8 T-cell
response, both indicating that the acute expansion in pre-immune
mice does not directly correlate with memory cell levels.
Adenovirus-primed CD8 T cells tend to be dominated by cells
with an effector-memory like phenotype [22,23]. Therefore,
having found that GP specific memory CD8 T-cell numbers
could be boosted in pre-immune wt mice using the same vector, it
became of interest to see whether two Ad5 vaccinations would
cause a further terminal differentiation of the induced memory
cells. To this end, we measured the expression of the phenotypical
markers CD27, CD127 and KLRG1 on the memory CD8 T cells
generated after one or two vaccinations; combinations of these
markers is commonly used to define different phenotypes of
memory cells [24,25]. However, the expression of all markers was
similar irrespectively of whether the mice had been subjected to
one or two vaccinations (Fig. S2), indicating that boosting of
adenoprimed memory CD8 T cells is not associated with a
significant change in the state of their differentiation.
On the role of vaccination route
Since it is a major finding of our study that we tend to observe
much better CD8 T-cell priming in vector-immune animals than it
is reported in the literature, we sought to explain this discrepancy.
One obvious factor could be the way in which we present the
antigen. Thus tethering of the transgene to invariant chain
obviously would seem to play a major role, cf. Fig. 1. However,
also the fact that we used s.c. immunization as opposed to i.m.
vaccination used in most published studies, could be relevant. To
address the relative importance of these factors, we performed an
experiment in which two large groups of mice were either
vaccinated with Ad5-IiOva or left untreated. Two months later,
mice from both groups were vaccinated i.m. or s.c. with Ad5-IiGP
or Ad5-GP, and the transgene-specific CD8 T-cell response was
evaluated (Fig. 10). Similar results were obtained using both
epitopes except in the case of mice vaccinated with Ad5-GP, in
which mice a GP276-specific cannot be detected no matter the
route of vaccination. Irrespective of route of vaccination and
vector construct, the induced CD8 T cells seemed to be subject to
the same relative reduction in vector -immune mice as compared
to vector-naı ¨ve animals. However, because the tethered construct
was much more immunogenic than the conventional construct, a
sizable T-cell response could still be observed in vector-immune
mice given the former, whereas the transgene-specific T-cell
response in vector–immune mice given the conventional construct
borders on the level of detection. Regarding the role of route of
vaccination, no major difference was observed; however, due to
the fact that i.m. vaccination was associated with a lesser immune
response than s.c. immunization even in vector-naı ¨ve mice,
responses tended to be lower also in i.m. vaccinated vector-
immune mice.
Discussion
This study focuses on how prior encounter with adenovirus
impacts a transgene specific CD8 T-cell response induced by
vaccination with the same adenoviral vector. Earlier studies have
shown that Ad5 induces a humoral and cellular immune response
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same vector [2,3,12]. Following these discoveries, there have been
several studies focusing on changing the serotype of the virus used
for vaccination or modifying the hexon proteins on the surface of
the Ad5 capsid [13,26–30]. However, having devised a way to
improve the stimulatory capacity of transgenes expressed from
adenoviral vectors, we found it pertinent to revisit the subject of
inhibitory immunity in pre-immune hosts and to clarify the full
extent of inhibition on the generation of memory and secondary
effectors cells, since this would have important implications for the
design of future vaccines.
Using our optimized vector system, we still observed an
inhibitory effect on the transgene specific CD8 T-cell response
when the mice have pre-existing immunity to the Ad5 vector, and
the same phenomenon was observed for the Ad35 vector (data not
shown). As to the underlying mechanism, although published data
indicate that antibodies are important as mediators of the
inhibition observed in mice with pre-existing immunity to the
viral vector [2,3], T cells have also been implicated and, notably,
complementary analysis in B-cell deficient mice has not previously
been performed. Strongly supporting a role for antibodies, we
observed not only that transfer of serum from Ad5 vaccinated
donors caused a marked reduction in the number of antigen
specific CD8 T cells induced by Ad5 vaccination in the recipients,
but also that the transgene specific response was not significantly
reduced by prior encounter with Ad5 in previously vaccinated B
cell deficient mice, and that re-vaccination with an Ad5 vector
expressing the same antigen induced robust secondary responses in
the latter mice. Finally, the inhibitory effect of pre-existing
immunity could be overcome by vaccinating mice with in vitro
Ad5 loaded DCs, that mask the adenovirus particles from
recognition by antibodies.
However, pre-existing antibodies do not explain everything.
Thus, in B-cell deficient mice we found that after two and three
Ad5 vaccinations, numbers of Ad5 specific CD8 T cells were
substantially increased, a phenomenon not observed in wt mice
(data not shown). Moreover, mice with an increased number of
adenovirus specific CD8 T cells after three Ad5 vaccinations had a
Figure 8. Pre-existing immunity reduces, but does not prevent secondary expansion of transgene-specific CD8 T cells. A. Mice were
vaccinated with Ad5-IiGP, followed by a second vaccination with the same vector on day 40. The GP-specific CD8 T cell response was measured on
days 5, 8 and 11 after the second vaccination; mice given a single vaccination with Ad5-IiGP 11 days earlier served as positive controls. B. Mice were
primed using an Ad35-IiGP vector and about two month later given Ad5-IiGP. The GP-specific CD8 T cell response was measured on days 5, 8 and 11
after the second vaccination; mice given a single vaccination with Ad5-IiGP 11 days earlier served as positive controls. C. B-cell deficient mice were
primed using Ad5-IiGP, followed by a second vaccination with the same vector about two months later. The GP-specific CD8 T cell response was
measured on days 8 and 11 after the second vaccination; mice given a single vaccination with Ad5-IiGP 11 days earlier served as positive controls.
doi:10.1371/journal.pone.0034884.g008
Figure 9. Memory cell expansion in previously vaccinated mice. Mice were vaccinated with Ad5-IiGP followed by a second vaccination with
the same vector 40 days later, and the GP-specific CD8 T cell response was measured on day 60 after the final vaccination. Controls consisted of mice
vaccinated once with the same vaccine either at the time of first immunization or simultaneously with the booster dose.
doi:10.1371/journal.pone.0034884.g009
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compared to mice vaccinated only once. The GP276 specific
response showed the same tendency, but in this case there was no
statistical significance. Since antibodies can be ruled out as a cause
of inhibition in these mice, the results support the idea that T cells
might also contribute to the inhibitory effect of prior encounter, at
least in a context where antibodies are not able to neutralize the
virus. Pertinent to this hypothesis, it should be noted that Sumida
et al. [3] have claimed an inhibitory effect of an Ad5 induced CD8
T-cell response based on adoptive transfer of primed splenocytes
to naı ¨ve recipients. We have not been able to reproduce this
observation (data not shown). However, this could be a matter of
variations in virus dose (10
10 vs. 2610
7) and/or mouse strain
(BALB/c vs. C57BL/6) employed. Another study that points to
some degree of T-cell involvement in the inhibition associated with
pre-existing immunity was performed by Osada et al. [9] who
observed that an E1, E2b and E3 deleted vector induced an
immune response of the same magnitude in naı ¨ve and previously
vaccinated mice. These authors hypothesized that this was due to
a significantly lower production of late proteins such as the hexon
protein after infection of DCs in vivo, which might mean that DCs
are not cleared so rapidly by CD8 T cells allowing the immune
response to develop in spite of the presence of adenovirus-specific
CD8 T cells. If this hypothesis holds true, there seems to be some
involvement of T cells in mediating the inhibitory effect of pre-
existing immunity to adenoviral vectors.
Having confirmed that pre-existing immunity to the vector
markedly interferes with the induction of a primary effector CD8
T-cell response, we found it pertinent to investigate whether the
clonal expansion of memory T cells was repressed to the same
degree, since the available number of memory cells would be of
primary importance in regard to the ability to mount efficient
recall responses upon antigen challenge. We observed that the
number of memory CD8 T cells was significantly lower in animals
Figure 10. Influence of vector configuration and route of vaccination. Groups of mice were either vaccinated with Ad5-IiOva or left
untreated. Two months later, mice from both groups were vaccinated i.m. or s.c. with Ad5-IiGP or Ad5-GP, and the transgene-specific CD8 T-cell
response was evaluated. Results for GP276 in mice vaccinated with Ad5-GP have not been not been included as this vector construct does not cause
a clearly detectable CD8 T-cell response even in vector-naı ¨ve mice. Dotted lines denote limit of detection for IFN-c
+ CD8 T cells as determined by
analysis of unstimulated cells.
doi:10.1371/journal.pone.0034884.g010
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memory cell level in these mice was not reduced to the same
degree as the primary effector response. This observation led us to
investigate the ability of the remaining memory CD8 T cells to
respond to challenge with live virus expressing the antigen used for
vaccination. We found that the memory cells induced in the face of
inhibitory immunity responded well to the viral challenge, and
only the GP276 specific response was significantly lower in mice
with a repressed memory level. Furthermore, irrespective of the
state of vector immunity at the time of vaccination, vaccinated
mice were able to rapidly control a high dose challenge with highly
infectious LCMV clone 13. These findings have obvious and
important implications regarding the use of the Ad5 vector in
immune individuals, because they indicate that even though the
primary Ad5 induced response may be repressed in vector-
immune individuals, these may still be able to mount efficient
recall responses upon viral re-challenge.
Secondary immune responses have a lower threshold for
activation, a faster kinetics, and result in the generation of higher
numbers of antigen specific cells compared to primary immune
responses. As expected from this, we saw a significantly smaller
impact of pre-existing immunity on the ability of the Ad5 vector to
induce a secondary immune response. Notably, the magnitude of
the recall response was not higher than a normal primary
response, but the response did exhibit the accelerated kinetics of a
secondary immune response.
Having observed a diminished inhibitory effect of pre-existing
immunity on memory cell formation in Ad5-immune mice, we
asked whether CD8 T-cell memory could be boosted by a second
vaccination with the same virus vector. We observed that the
number of GP276 specific memory CD8 cells was higher in mice
vaccinated twice with the Ad5-IiGP vector, which indicates that
even though the magnitude of the effector response is not
increased after two vaccinations, some expansion of the memory
CD8 T-cell pool may still occur. Numbers of GP33 specific
memory CD8 T cells also tended to be higher in mice vaccinated
twice with Ad5; however, in this case the difference was not
statistically significant. Notably, the phenotype of antigen specific
CD8 T cells induced by two vaccinations was similar to the
phenotype of memory cells induced by only one vaccination,
which is important for vaccine purposes where it is important to
sustain an expanded memory population without driving the
involved cells towards replicative senescence.
In the current study, we found much better CD8 T-cell priming
in vector- immune animals than has previously been reported in
the literature [1,4,13]. This predominantly reflects the improved
immunogenicity of our construct resulting from tethering of the
transgene product to invariant chain. Using the optimized
construct, dose-response analysis revealed that even assuming
99% neutralization of applied inoculum, a transgene-specific CD8
T-cell response would be induced, which matches that in vector-
naı ¨ve mice given an optimal dose of a classical vector construct.
Also the route of vaccination seems to play a role. Thus, despite a
similar relative reduction in the CD8 T-cell response following s.c.
and i.m. vaccination of vector-immune mice, the fact that s.c.
vaccination overall tends to induce a stronger response, leaves
room for a slightly better response in vector-immune mice when
vaccinated s.c. compared to i.v.
We find it to be of particular importance that quite substantial
recall responses could be observed in recipients with pre-existing
immunity towards the vector at the time of first vaccination. This
could indicate that our optimized Ad5 vector can be used even in
Ad5- immune individuals, albeit with slightly reduced efficiency. If
this holds generally true, and we have results suggesting that it is
the case also for Ad35, this would have important implications for
the design of vaccine strategies utilizing adenoviral vectors, since it
removes some of the need for a substantial combinatorial library of
different vectors in order to sustain the immune response, e.g. in
the case of cancer patients where prolonged immune pressure is
likely to be important for successful therapy [31,32]. Instead, it
would be possible to combine a limited number of potent vectors,
which each could be used more than once and still sustain an
efficient effector CD8 T-cell response for a significant period of
time.
Supporting Information
Figure S1 Inhibition of the primary immune response
is present up to 10 months after initial vaccination. Mice
were initially vaccinated with Ad5-IiOva followed by a second
vaccination with Ad5-IiGP 1, 2, 4, 6, 8 or 10 months later. The
GP specific CD8 T cell response was measured 11 days after the
second vaccination. For each pre-immunized animal, the mea-
sured response was compared to the average of responses in a
matched control group of 4–5 previously naı ¨ve mice, and from this
comparison, percent responsiveness was calculated. The spread in
the degree of inhibition matches with a similar spread in
antibodies titers of previously adenoexposed mice. Thus, in a
group of 14 randomly chosen mice, we observed neutralizing
antibody titers varying between hardly detectable and 1:640
(median=1:40).
(TIF)
Figure S2 Expression of the phenotypical markers
CD27, CD127 and KLRG1 on transgene specific memory
CD8 T cells generated after one or two vaccinations with
Ad5. Mice were vaccinated as described in fig. 9 and the
expression of CD27, CD127 and KLRG1 on the GP specific
memory CD8 T cells was measured on the indicated days.
Representative contour plots on gated GP33-specific (IFN-c
+)
CD8 T cells are depicted to the right.
(TIF)
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